A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome
ClinicalTrials.gov NCT03473223
Research payments
$150,123,977
Through program year 2025, $150,123,977 in research payments was reported against A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome, across 10,749 payments, paid by CSL Behring.
- Paid by
- CSL Behring
- ClinicalTrials.gov
- NCT03473223
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $429,636 | 7 |
| 2024 | Research | $12,823,605 | 653 |
| 2023 | Research | $23,794,503 | 1,091 |
| 2022 | Research | $20,457,519 | 3,031 |
| 2021 | Research | $27,222,172 | 2,672 |
| 2020 | Research | $35,873,569 | 3,255 |
| 2019 | Research | $29,522,973 | 40 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Alan Wiseman Bangor, ME Named on 135 payments
- Nabil Dib Gilbert, AZ Named on 122 payments
- John McGinty Richmond, IN Named on 113 payments
- Fahed Bitar Covina, CA Named on 112 payments
- Farhad Rafii West Hills, CA Named on 111 payments
- Charles Treasure Knoxville, TN Named on 109 payments
- Vijay Mehta Elkhart, IN Named on 102 payments
- Tinoy Kizhakekuttu Peoria, IL Named on 101 payments
- Alfred Chu Amarillo, TX Named on 97 payments
- Brian Foley Alexander City, AL Named on 95 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.